



Ian F. Hlatky

Associate

ian.hlatky@dlapiper.com

Los Angeles (Century City)

T: +1 310 595 3023

F: +1 310 595 3453

M: +1 303 668 4295

Silicon Valley

T: +1 650 833 2000

Ian Hlatky focuses his practice on helping high-growth, technology-based companies across market sectors navigate the diverse corporate matters that arise throughout a company's life cycle, from initial planning, formation and structuring, to seed, convertible debt, and venture capital financing, to general corporate governance and mergers and acquisitions.

Ian also regularly represents venture capital and corporate venture capital clients as outside counsel during portfolio company investments, including BlueRun Ventures, Canvas Ventures, Congruent Ventures, Danone Manifesto Ventures, Elysian Park Ventures, GE Ventures, General Atlantic, Lenovo Capital, Lux Capital, March Capital, Mubadala Capital Ventures, Nautilus Venture Partners, New Enterprise Associates, Novartis Pharma, Propel Venture Partners, Riverwood Capital, S7 Investment Company, Samsung Oak Ventures, Samsung Venture Investment Corporation, Softbank Group International, SoftBank Vision Fund, Sozo Ventures, Tallwood Ventures, Tank Hill Venture Partners, Transamerica Ventures and Wireframe Venture Capital.

- Emerging Growth and Venture Capital
- Corporate
- Mergers and Acquisitions

- Technology
- Energy and Natural Resources
- Hospitality and Leisure
- Media, Sport and Entertainment
- Life Sciences

Admissions

- California

Education

- J.D., University of California, Davis School of Law
- B.A., University of Colorado, Denver
summa cum laude

NEWS

DLA Piper advises Sharp Alpha Advisors in formation of US\$10 million venture fund

13 October 2021

DLA Piper represented Sharp Alpha Advisors in the formation and closing of Sharp Alpha Fund I, an oversubscribed US\$10 million venture capital fund investing in early-stage sports betting technology companies.

DLA Piper advises Sidecar Health in US\$125 million Series C financing

3 February 2021

DLA Piper represented health insurtech company Sidecar Health in its recent US\$125 million Series C financing, resulting in its subsequent valuation at US\$1 billion.
